Codex DNA, Inc. (DNAY): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
DNAY Stock Price Chart Interactive Chart >
DNAY Price/Volume Stats
|Current price||$10.53||52-week high||$25.70|
|Prev. close||$10.15||52-week low||$9.53|
|Day high||$10.73||Avg. volume||147,715|
|50-day MA||$13.97||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||308.44M|
Codex DNA, Inc. (DNAY) Company Bio
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Most Popular Stories View All
DNAY Latest News Stream
|Loading, please wait...|
DNAY Latest Social Stream
View Full DNAY Social Stream
Latest DNAY News From Around the Web
Below are the latest news stories about Codex DNA Inc that investors may wish to consider to help them evaluate DNAY as an investment opportunity.
This afternoon, Codex DNA released its financial results for the second quarter ended June 30, 2021. Joining me today from Codex DNA, are Todd Nelson, our chief executive officer, and Dan Gibson, our chief technology officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws.
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. “During the second quarter, Codex DNA took a big step forward in the evolution of our business. We successfully closed an IPO, strengthened the diversity of our leadership team and Board of Directors, enabled new downstream mRNA applications, expanded our customer base, and grew revenue
Codex DNA Announces Synthetic Biology Collaboration with U.S. Department of Agriculture to Combat Citrus Greening Disease
Codex DNA to contribute novel synthetic biology-based solutions to stop the spread of a global disease that continues to devastate the citrus industrySAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a collaboration with researchers from the U.S. Department of Agriculture’s (USDA) Agricultural Research Service (ARS), Cornell University, the University of Florida, the University of California at
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company management will host a conference call on Tuesday, August 10, 2021, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accesse
Wall Street’s analysts know that buying low is part of a winning stock strategy, and they’ve been looking for stocks that are low – undervalued, and possibly hitting bottom. It’s the first step in an old formula for success, with the next, of course, being to sell high. Some recent picks from the analyst corps, pulled up via the TipRanks platform, may raise eyebrows. These are stocks new to the public trading markets, but they already have two attributes that may endear them to risk-tolerant inv
DNAY Price Returns